Report overview
Non-viral vectors for gene therapy are non-viral vehicles (particle based or chemical based) that deliver the genetic material into a wide variety of cells, tissues and whole organs to treat or improve the health condition of the patient.
This report contains market size and forecasts of Non-viral Vectors Gene Therapy in Global, including the following market information:
Global Non-viral Vectors Gene Therapy Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-viral Vectors Gene Therapy market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Oligonucleotides Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Non-viral Vectors Gene Therapy include Biogen, Sarepta Therapeutics, Gilead Sciences, Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics and Anges, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-viral Vectors Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-viral Vectors Gene Therapy Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Non-viral Vectors Gene Therapy Market Segment Percentages, by Type, 2022 (%)
Oligonucleotides
Other Non-viral Vectors
Global Non-viral Vectors Gene Therapy Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Non-viral Vectors Gene Therapy Market Segment Percentages, by Application, 2022 (%)
In Vivo
Ex Vivo
Global Non-viral Vectors Gene Therapy Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Non-viral Vectors Gene Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-viral Vectors Gene Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-viral Vectors Gene Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Sarepta Therapeutics
Gilead Sciences
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
